INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Robbins Geller

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading information about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided investors with misleading information regarding the Phase 2 pivotal trial of RP-A501 for Danon disease, while concealing serious risks, including the death of participants [3]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without disclosing this critical update to shareholders [3]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event, including a participant's death, the stock price of Rocket Pharmaceuticals fell significantly [4]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].